**Abstract**

**Objectives**: Clozapine is indicated for Treatment Resistant Schizophrenia (TRS) yet only 30--60% of patients will respond to optimum treatment. There have been studies of clozapine augmentation with oral second generation antipsychotics (SGA) with mixed results but no studies considering the combination with long acting injectable (LAI) antipsychotics. This study attempts to establish the efficacy of the combination of clozapine and LAI antipsychotics in TRS.

**Methods**: A mirror-image study design was employed to review health care utilization measures 2 years pre and post combination of clozapine with a LAI (either first generation antipsychotic (FGA) or SGA) in a small sample of patients (*N*=20) with chronic psychotic disorders followed by the Assertive Community Treatment service in Calgary, Alberta.

**Results**: Paired sample t tests showed a statistically significant reduction in average ED visits in the two years post combination with an average 1.8 fewer ED visits (95%CI = \[0.58 to 3.02\], *p*=0.024). There was also a statistically significant reduction in number of hospital admissions in the 2 year post combination with a mean reduction of 0.85 admissions (95%CI = \[0.36 to 1.34\], *p*=0.008). There was no statistically significant reduction in hospital bed days between pre- and post-combination.

**Conclusions**: The combination of clozapine and a long acting injectable antipsychotic appears to reduce health care utilization in terms of ED visits and number of hospital admissions. Future research will investigate the effects of this combination on psychopathology and health related quality of life outcomes in this patient population.
